核苷类似物治疗的慢性乙型肝炎患者合并肝癌的临床特征分析

肝脏 ›› 2020, Vol. 25 ›› Issue (2): 172-174.

核苷类似物治疗的慢性乙型肝炎患者合并肝癌的临床特征分析

刘莉, 唐世刚

410000 长沙湖南省人民医院(湖南师范大学附属第一医院)感染科

收稿日期:2019-05-31 出版日期:2020-02-29 发布日期:2020-03-26
基金资助:
湖南省卫生健康委员会科研基金(20200034)

Received:2019-05-31 Online:2020-02-29 Published:2020-03-26

摘要/Abstract

摘要： 目的慢性乙型肝炎合并肝细胞癌的临床特征在核苷类似物治疗的病人和无核苷类似物治疗的病人之间存在显著差异。为了更好地了解慢性乙型肝炎合并肝癌的临床特点,我们比较了有无核苷类似物治疗的肝癌的临床特点。方法对湖南省人民医院2008年1月1日至2017年12月31日收治的76例肝癌患者的病历资料进行回顾性分析,根据有无核苷类似物治疗分为抗病毒组和非抗病毒组。结果抗病毒组肝区疼痛和食欲减退的比例明显低于未抗病毒组(36.36% vs 79.07%,P<0.05)(30.30% vs 70.27%,P<0.05);未抗病毒组患者HBV DNA阴性的比例明显低于抗病毒组(11.63% vs 63.64%,P<0.05) ,抗病毒组患者ALT正常的比例明显高于未抗病毒组(75.76% vs 25.58%,P<0.05),两组具有明显统计学差异;TBil(31.39±5.96 vs 43.37±11.37,P=0.370)、Alb(35.76±1.26 vs 35.39±0.94,P=0.475)两组比较无统计学差异;HBeAg阴性(96.97%vs95.35%,P=0.719)的比例两组无统计学差异;单一肿瘤结节在核苷类似物治疗患者中更常见(66.67% vs 6.98% , P<0.05);观察门静脉侵犯(18.18% vs 79.07%, P<0.05)和肝外转移(0% vs 44.19%, P<0.05),两组有明显差异;符合米兰标准(69.70% vs 11.63% , P<0.05)的比例,两组之间也有明显的差异。结论核苷类似物对慢性乙型肝炎合并肝细胞癌的临床及影像学特征有重要影响,结果发现,接受核苷类似物治疗的患者症状较轻,影像学表现较少,预后明显改善。

刘莉, 唐世刚. 核苷类似物治疗的慢性乙型肝炎患者合并肝癌的临床特征分析[J]. 肝脏, 2020, 25(2): 172-174.

参考文献

[1] Zuo TT,Zheng RS,Zhang SW,et al.Incidence and mortality of liver cancer in China in 2010. Chin J Can,2015, 15:34:508-513.
[2] Wang JP,Kao FY,Wu CY,et al.Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients:a population-based cohort study.Cancer,2015,1:121:1446-1455.
[3] Wu CY,Lin JT,Ho HJ,et al.Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.Gastroenterol,2014,147:143-151.
[4] Wei L,Kao JH.Benefits of long-term therapy with nucleos(t)ide analogues in treatment-na?ve patients with chronic hepatitis B,Curr Med Res Opin,2017,33:495-504.
[5] Ando Y,Ishigami M,Ishizu Y,et al.Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment.Hepatol Res,2018,48:E240-E251.
[6] Hiramatsu N,Yamada R,Takehara T.The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.J Gastroenterol Heaptol,2016,31:546-552.
[7] Surveillance group, Diagnosis group, Staging group,et al.Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.J Formos Med Assoc,2018,117:381-403.
[8] Levrero M,Subic M,Villeret F,et al.Perspectives and limitations for nucleo(t)side analogs in future HBV therapies.Curr Opin Virol,2018,30:80-89.
[9] Jang JW,Choi JY,Kim YS,et al.effects of virologic response to treatment on short-and long-term outcomes of patients with chronic HBV infection and decompensated cirrhosis.Clin Gastroenterol Hepatol,2018, 16:1954-1963.
[10] Loqlio A,lavarone M,Grossi G,et al.Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.Aliment Parmacol Ther,2018 ,48:431-439.
[11] Budhu A, Wang XW.The role of cytokines in hepatocellular carcinoma. J Leukoc Biol,2006,80:1197-1213.
[12] Ma KW, Cheung TT. Surgical resection of localized hepa-tocellular carcinoma: patient selection and special consideration.J Hepatocell Carcinoma,2016,28:1-9.
[13] Piscaglia F,Ogasawara S.Patient selection for transarterial chemoebolization in hepatocellular carcinoma:importance of benefit/risk assessment.Liver Cancer,2018,7:104-119.
[14] Hu h,Chen GF,Yuan W,et al.Microwae ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis.Int J Hyperthermia,2018,34:1351-1358.